Physician profile
Robert A Dorman
NPI 1598764896
$644.12
in general payments reported to CMS, 2019-2025
14 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $140 · 2021: $54.64 · 2022: $14.08 · 2023: $30.69 · 2024: $19.04 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $212 · Food and Beverage: $49.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $212.38 |
| Food and Beverage | $49.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $212.38 | 2025 | |
| Allergan, INC. | $66.66 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.25 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $53.64 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.76 | 2019-2020 | |
| Pfizer INC. | $37.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.26 | 2019-2020 | |
| Novo Nordisk INC | $27.92 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $22.29 | 2020-2021 | |
| Abbott Laboratories | $19.82 | 2019 | |
| Dexcom, INC. | $19.04 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $14.19 | 2023 | Ubrelvy |
| Lilly USA, LLC | $14.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.